en · de · es · fr · pt
analytical-notes.peptides9002.com › Wiki › Background And Receptor Mechanism — Field Notes

Background And Receptor Mechanism — Field Notes

By Editorial Desk · published 2025-07-04 · last reviewed 2025-08-11 · Wiki

alpha-MSH analogue comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Updated 2025-08-11. Numbers and descriptions here follow the published literature rather than marketing material.

Background and Receptor Mechanism

Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.

Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.

Melanotan-2 Identity and Receptor Pharmacology

Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.

Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.

Melanotan-2 at a glance

PropertyValueNotes
Chemical classSynthetic cyclic heptapeptideAnalog of alpha-melanocyte-stimulating hormone
Primary receptor familyMelanocortin receptors MC1R through MC5RBinding is not subtype-selective
Development period1980sSynthesized during pigmentation and appetite research
Regulatory statusNot an approved medicineNo major regulator has authorized human use
Related compoundAfamelanotideLinear analog studied for photoprotection

Peptide Identity and Structural Background

The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.

Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.

Related pages on this site

Chemistry and Receptor Pharmacology

Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.

Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.

Reference notes

The majority of mummies recovered in the Czech Republic come from underground crypts. While there is some evidence of deliberate mummification, most sources state that desiccation occurred naturally due to unique conditions within the crypts. The Capuchin Crypt in Brno contains three hundred years of mummified remains directly below the main altar. Beginning in the 18th century when the crypt was opened, and continuing until the practice was discontinued in 1787, the Capuchin friars of the monastery would lay the deceased on a pillow of bricks on the ground. The unique air quality and topsoil within the crypt naturally preserved the bodies over time. Approximately fifty mummies were discovered in an abandoned crypt beneath the Church of St. Procopius of Sázava in Vamberk in the mid-1980s. Workers digging a trench accidentally broke into the crypt, which began to fill with waste water. The mummies quickly began to deteriorate, though thirty-four were able to be rescued and stored temporarily at the District Museum of the Orlické Mountains until they could be returned to the monastery in 2000. The mummies range in age and social status at time of death, with at least two children and one priest. The majority of the Vamberk mummies date from the 18th century. The Klatovy catacombs currently house an exhibition of Jesuit mummies, alongside some aristocrats, that were originally interred between 1674 and 1783. In the early 1930s, the mummies were accidentally damaged during repairs, resulting in the loss of 140 bodies.

=== Sheep === In sheep, ketosis, evidenced by hyperketonemia with beta-hydroxybutyrate in blood over 0.7 mmol/L, is referred to as pregnancy toxemia. This may develop in late pregnancy in ewes bearing multiple fetuses and is associated with the considerable metabolic demands of the pregnancy. In ruminants, because most glucose in the digestive tract is metabolized by rumen organisms, glucose must be supplied by gluconeogenesis. Pregnancy toxemia is most likely to occur in late pregnancy due to metabolic demand from rapid fetal growth and may be triggered by insufficient feed energy intake due to weather conditions, stress or other causes. Prompt recovery may occur with natural parturition, Caesarean section or induced abortion. Prevention through appropriate feeding and other management is more effective than treatment of advanced stages of pregnancy toxemia.

==== Digestion ==== In human digestion, proteins in food are broken down into smaller peptide chains by digestive enzymes such as pepsin, trypsin, chymotrypsin, and elastase, and into amino acids by various enzymes such as carboxypeptidase, aminopeptidase, and dipeptidase. It is necessary to break down proteins into small peptides (tripeptides and dipeptides) and amino acids so they can be absorbed by the intestines, and the absorbed tripeptides and dipeptides are also further broken into amino acids intracellularly before they enter the bloodstream. Different enzymes have different specificity for their substrate; trypsin, for example, cleaves the peptide bond after a positively charged residue (arginine and lysine); chymotrypsin cleaves the bond after an aromatic residue (phenylalanine, tyrosine, and tryptophan); elastase cleaves the bond after a small non-polar residue such as alanine or glycine. In order to prevent inappropriate or premature activation of the digestive enzymes (they may, for example, trigger pancreatic self-digestion causing pancreatitis), these enzymes are secreted as inactive zymogen. The precursor of pepsin, pepsinogen, is secreted by the stomach, and is activated only in the acidic environment found in stomach. The pancreas secretes the precursors of a number of proteases such as trypsin and chymotrypsin. The zymogen of trypsin is trypsinogen, which is activated by a very specific protease, enterokinase, secreted by the mucosa of the duodenum.

== As an allergenic == Eugenol is subject to restrictions on its use in perfumery, as some people may become sensitised to it, however, the degree to which eugenol can cause an allergic reaction in humans is disputed. Eugenol is a component of balsam of Peru, to which some people are allergic. When eugenol is used in dental preparations such as surgical pastes, dental packing, and dental cement, it may cause contact stomatitis and allergic cheilitis. The allergy can be discovered via a patch test.

For services to Online Safety. Nathaniel Timothy Hepburn. Director and Chief Executive, Charleston. For services to the Arts. Ian Leslie Hewitt. Lately Chairman, All England Lawn Tennis Club. For services to Tennis and to Charity. Dr. Alison Maynard Hill. Chair, Bikeability Trust, and Chair, Cyclox. For services to Cycling. Daniel Peter Hill. Director, Daddys with Angels. For charitable services to Bereaved Families. Nicholas Andrew Hill. National Conservation Projects Manager. For services to Heritage. Martyn Paul Hillier. Founder, Micropub Association. For services to Business and to Hospitality. Geraldine Hills. Founder, Manchester Parent Champions. For services to Children and Young People with Special Educational Needs and Disabilities. Stuart William Hogg. For services to Rugby Union Football. Paul Hollywood. Baker and Television Presenter. For services to Baking and to Broadcasting. Helen Holtam. Tutor, Friends of Erlestoke Prison, Origami Inside. For services to Prisoners. Glennis Edith Hooper. For Charitable Services to People with Breast Cancer. Susan Hornby. Co-Founder and Head Teacher, The Bridge School Malvern. For services to Disadvantaged Children. Helen Housby. For services to Netball. Joslyn Hoyte-Smith. Chair, GB Olympians Association. For services to Athletics. Ian Russell Hughes. Director of Policy, Local Government Association. For services to Local Government. Air Commodore Paul Jonathan Hughesdon. Lately Director of Welfare, Royal Air Force Benevolent Fund. For services to Veterans. Christopher Neil Hunter Gordon. Chairman, Resources for Autism.

Sources: en.wikipedia.org

Reference notes

== Record and specimen retention == CLIA and the College of American Pathologists (CAP) have written policies for the minimum period that laboratories should keep laboratory records and materials, with some examples as follows:

== Overdose == Glucagon, used in the treatment of overdose, increases the strength of heart contractions, increases intracellular cAMP, and decreases renal vascular resistance. It is, therefore, useful in patients with beta blocker cardiotoxicity. Cardiac pacing is usually reserved for patients unresponsive to pharmacological therapy. People experiencing bronchospasm due to the β2 receptor-blocking effects of nonselective beta blockers may be treated with anticholinergic drugs, such as ipratropium, which are safer than beta agonists in patients with cardiovascular disease. Other antidotes for beta blocker poisoning are salbutamol and isoprenaline.

== Management == D. dadantii is a member within the genus that is able to produce the pigment indigoidine. Rapid identification of this species utilizes this water-insoluble blue pigment appearing in the bacterial colonies as a chemotaxonomic trait. The presence of a soft rot may be an indication of a bacterial disease. However, many other organisms and plant disorders may appear as various soft rot or black lesions. Proper identification is important for treatment and control measures. Thus a differential media is used to culture Dickeya species and isolate or identify D. dadantii. Researchers at Fu Jen Catholic University in Taiwan developed a medium that differentiates D. dadantii from other species. This NGM medium contains nutrient agar (NA) and glycerol medium supplemented with MnCl2 :4H2O. To make this media, mix 23 g of nutrient agar, 10 ml glycerol (1% v/v), and 0.4 g MnCl2:4H2O (2 mM) to 1.0 liter of water. Note the pH of this media is 6.5 and it has a light brown base color. The proper temperature for culturing D. dadantii is 28 degrees Celsius. A positive result occurs when a bacterial streak produces a brownish blue color on the agar plate. Further isolation and extraction of the indigoidine pigment is possible using the methods described by Chatterejee and Brown. Currently there are no effective chemical controls for D. dadantii. The most important practices involve lowering the prevalence of disease by proper sanitation of materials, exclusion of infected materials, and avoiding environments conducive to disease.

=== Eligibility for different stages of treatment === While a mental health assessment is recommended as standard practice by the WPATH Standards of Care (SoC), psychotherapy is not an absolute requirement but is highly recommended. Hormone replacement therapy is to be initiated from a qualified health professional. The general requirements, according to the WPATH standards, include:

Sources: en.wikipedia.org

Frequently asked questions

Is melanotan II an approved medication?

No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.

How does it differ from afamelanotide?

Afamelanotide is a linear analog that has received approval in some jurisdictions for a specific photoprotection indication. Melanotan II is cyclic and less selective across melanocortin receptors. The two are related but are not interchangeable in regulatory or clinical terms.

Why does receptor selectivity matter?

A compound that activates several receptor subtypes may produce effects beyond pigmentation. Selectivity influences which tissues respond and shapes the side-effect profile described in reports. Designing subtype-selective analogs is a stated goal of melanocortin research.

What is melanotan-2 chemically?

It is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, containing seven amino acids with a lactam ring and a D-configured phenylalanine residue. It is supplied as a lyophilised powder for laboratory research.

Network